Low
NA
$150/day+
Renally cleared, requires dosage adjustment with changes in renal function. Consult a pharmacist for renal dosing.
Not routinely used as first-line therapy. The manufacturer recommends avoiding use in patients <12 months due to musculoskeletal, neuromuscular, and nervous system adverse effects observed in neonatal canine models
2 to 5 Years10 mg/kg/dose IV q24h
6 to 11 Years7 mg/kg/dose IV q24h
Greater than 12 years4-6 mg/kg/dose IV q24h
Targeted therapy of resistant gram positive infections with MRSA (particularly when MIC>=2) and VRE including endovascular infection
Myopathy including rhabdomyolysis, GI side effects common, rash, phlebitis, increased INR
Statins and fibrates: monitor creatine kinase or hold while on daptomycin therapy (increased myopathy)
Recommend Infectious Disease Consult
Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection
Antimicrobial class: Cyclic lipopeptide, depolarizes bacterial cell membrane
Average serum half life: Neonates and Infants <3 months: 6.2 hours. Children: 5 to 7 hours
Route of Elimination: 78% of the dose excreted in urine as unchanged drug; feces (6%)
